Cargando…

Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies

Mostrar otras versiones (1)

Patients with hematologic malignancies have both an increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and higher morbidity/mortality. They have lower seroconversion rates after vaccination, potentially leading to inferior coronavirus disease 2019 (COVID-19) o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chien, Kelly S., Peterson, Christine B., Young, Elliana, Chihara, Dai, Manasanch, Elizabet E., Ramdial, Jeremy L., Thompson, Philip A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Health Services and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896882/ https://www.ncbi.nlm.nih.gov/pubmed/36696472 http://dx.doi.org/10.1182/bloodadvances.2022008827

Ejemplares similares

Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies
por: Chien, Kelly S., et al.
Publicado: (2022)

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub
por: Wood, William A., et al.
Publicado: (2020)

Coping in caregivers of patients with hematologic malignancies undergoing hematopoietic stem cell transplantation
por: Amonoo, Hermioni L., et al.
Publicado: (2022)

Outcomes before and after providing interdisciplinary hematology and pulmonary care for children with sickle cell disease
por: Zeno, Rachel N., et al.
Publicado: (2022)

ASH Research Collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology
por: Wood, William A., et al.
Publicado: (2021)

Influence of participant and reviewer characteristics in application scores for a hematology research training program
por: Vesely, Sara K., et al.
Publicado: (2023)

Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
por: Wang, Rong, et al.
Publicado: (2022)

Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy
por: Johnson, P. Connor, et al.
Publicado: (2023)

Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study
por: Bankar, Aniket, et al.
Publicado: (2023)

Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists
por: Stojkov, Igor, et al.
Publicado: (2021)

Preliminary construct validity of patient-reported outcomes to assess chronic pain in adults with sickle cell disease
por: Mucalo, Lana, et al.
Publicado: (2023)

The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States
por: Sacks, Naomi C., et al.
Publicado: (2022)

Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report
por: Lee, Thomas D., et al.
Publicado: (2023)

Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia
por: Fingrut, Warren B., et al.
Publicado: (2022)

COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals
por: Singh, Ashima, et al.
Publicado: (2021)

Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials
por: Hantel, Andrew, et al.
Publicado: (2021)

How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines
por: Nieuwlaat, Robby, et al.
Publicado: (2021)

Portable medical orders and end-of-life measures in acute myeloid leukemia and myelodysplastic syndromes
por: LoCastro, Marissa, et al.
Publicado: (2021)

Precancer and cancer-associated depression and anxiety among older adults with blood cancers in the United States
por: Kuczmarski, Thomas M., et al.
Publicado: (2022)

Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
por: Delforge, Michel, et al.
Publicado: (2022)

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)

Code status transitions in patients with high-risk acute myeloid leukemia
por: Abrams, Hannah R., et al.
Publicado: (2022)

Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance
por: Johnson, Kate M., et al.
Publicado: (2022)

Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis
por: Luan, Danny, et al.
Publicado: (2022)

Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma
por: O’Donnell, Elizabeth K., et al.
Publicado: (2022)

What do patients think about palliative care? A national survey of hematopoietic stem cell transplant recipients
por: Barata, Anna, et al.
Publicado: (2023)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Consensus recommendations on peripheral blood smear review: defining curricular standards and fellow competency
por: Chase, Matthew L., et al.
Publicado: (2023)

Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
por: Shallis, Rory M., et al.
Publicado: (2023)

Most adults with severe HbSC disease are not treated with hydroxyurea
por: Ghunney, William Kwesi, et al.
Publicado: (2023)

Health following recovery from immune thrombotic thrombocytopenic purpura: the patient’s perspective
por: Kelley, Rachel A., et al.
Publicado: (2022)

Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider support
por: Lee, Alfred Ian, et al.
Publicado: (2022)

Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy
por: Cronin, Robert M., et al.
Publicado: (2022)

Estimated mortality rates of individuals with sickle cell disease in Brazil: real-world evidence
por: Cançado, Rodolfo Delfini, et al.
Publicado: (2023)

Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL
por: Tam, Constantine, et al.
Publicado: (2023)

Inpatient Outcomes Following a Return Visit to the Emergency Department: A Nationwide Cohort Study
por: Tsai, Chu-Lin, et al.
Publicado: (2021)

Association of Vital Signs and Process Outcomes in Emergency Department Patients
por: Hodgson, Nicole R., et al.
Publicado: (2019)

Cancer-related Emergency Department Visits: Comparing Characteristics and Outcomes
por: Nene, Rahul V., et al.
Publicado: (2021)

Variability in the Initial Costs of Care and One-Year Outcomes of Observation Services
por: Abbass, Ibrahim
Publicado: (2015)

Musculoskeletal Injuries and Outcomes Pre- and Post- Emergency Medicine Training Program
por: Mattson, Peter, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ugu1udodm517s6gish635vdh5m